<DOC>
	<DOCNO>NCT02533258</DOCNO>
	<brief_summary>This post-marketing Surveillance study observe INLYTA® treatment dose pattern , safety effectiveness Taiwan real world routine practice . The primary objective registry monitor dose adjustment INLYTA® real world routine practice . The secondary objective include safety profile , objective response rate , progression-free rate real world routine practice .</brief_summary>
	<brief_title>Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern , Safety And Effectiveness In Taiwan Real World Routine Practice</brief_title>
	<detailed_description>This multi-center chart review registry mRCC patient treat axitinib . Primary objective dose adjustment . Secondary objective safety profile , objective response rate progression free survival . Efficacy assessment base investigator ' judgment . Patients treat 1st dose axitinib May 7 , 2013 June 30 , 2015 enrol . The follow-up time 12 month . Prior therapy include sunitinib interferon alpha .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients diagnose advanced RCC histology cytology Patients use axitinib therapy failure sunitinib cytokine Patients receive axitinib treatment follow health care center participate present registry Patients agree participate sign inform consent IRB waiving sign informed consent document available Patients first dose axitinib earlier 7th May 2013 Patients first dose axitinib later 30th June 2015 . Patients participate clinical research involve axitinib Patients hypersensitivity axitinib component axitinib Patients 18year age Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced renal cell carcinoma , disease progression , sunitinib , interferon alpha</keyword>
</DOC>